Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C8QA
|
|||
| Drug Name |
KITE-585
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1] | |
| Company |
Kite, A Gilead Company
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | CAR-T-Cell-Therapy | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.